Compare iShares MSCI Canada (TSX) (EWC) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Medpace Holdings Inc — how do they compare? iShares MSCI Canada (TSX) trades at $61.82, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| EWC | MEDP | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $61.51 | $620.59 |
52-Week Low | $47.00 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $61.77, up 0.44% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF shows strong 2026 performance, though trailing the S&P 500, and faces trade tensions as U.S. tariffs on Canadian goods loom, potentially impacting exports excluding energy and potash.
Outlook is mixed: growth drivers include Canada's record exports and active ETF trends, but risks from tariff escalations and political uncertainty weigh. Investors balance double-digit returns against trade war volatility, with key support at $61.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
